see also separate profiles for doravirine, lamivudine and tenofovir disoproxil
- TRADE NAME: Delstrigo (Merck Sharpe & Dohme)
- INDICATIONS: indicated as a complete regimen for the treatment of HIV-1 infection in adult patients with no antiretroviral treatment history.
- HALF-LIFE: 15 hours (doravirine); 5–7 hours (lamivudine); 17 hours (tenofovir disoproxil)
- FDA APPROVAL DATE: 08/30/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Carbamazepine, Enzalutamide, Ledipasvir & Sofosbuvir, Mitotane, Oxcarbazepine, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, Sofosbuvir & Velpatasvir, St John's Wort - PREGNANCY: insufficient data to adequately assess risk
POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B
See full prescribing information for complete boxed warning
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
